ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Other EventsItem 8.01 — Other Events.
Abbott today announced that with the process of integrating St. Jude Medical,Inc. proceeding and his planned transition period complete, Michael Rousseau, President of Abbott’s Cardiovascular and Neuromodulation business, will be leaving Abbott.
Effective July7, 2017, Robert Ford, Executive Vice President, Medical Devices, will assume leadership of this business in addition to the Vascular, Structural Heart, and Diabetes Care businesses.
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.
